Skip Navigation

Cardiovascular Research 1996 32(3):587-592; doi:10.1016/S0008-6363(96)00112-5
© 1996 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ruiz-Meana, M.
Right arrow Articles by Soler-Soler, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruiz-Meana, M.
Right arrow Articles by Soler-Soler, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1996, European Society of Cardiology

Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes

Marisol Ruiz-Meana*, David Garcia-Dorado, Margarita Juliá, Miguel A. González, Javier Inserte and J. Soler-Soler

Servicio de Cardiología, Hospital General Universitari Vall d'Hebron, Paseo Vall d'Hebron 119-129, Barcelona 08035, Spain

* Corresponding author. Tel. (+34-3) 4183400 (ext. 4948); fax: (+34-3) 4284301. dgdorado{at}ar.vhebron.es

Objective: Cytoskeletal and sarcolemmal fragility secondary to anoxia may contribute to sarcolemmal rupture and cell death during reoxygenation of cardiomyocytes. This study investigated the influence of trimetazidine (TMZ), a drug with effects on lipid metabolism and cell membranes, on reoxygenation-induced sarcolemmal rupture.Methods: Isolated adult rat myocytes were submitted to 60 min of metabolic inhibition and 5 min of hypo-osmotic reoxygenation to simulate reperfusion edema in situ. Cells were allocated to 3 groups of treatment: in one group, TMZ 100 µmol/1 was added to both the metabolic inhibition and reoxygenation buffers (group TMZ); another group was submitted to the same treatment but cells had previously been incubated with TMZ 100 µmol/1 for 3 h (group TMZ-Pre); a control group underwent metabolic inhibition and hypo-osmotic reoxygenation without any treatment. Cell morphology was monitored throughout the experiment and sarcolemmal integrity was assessed by quantification of LDH activity and trypan blue exclusion test.Results: After 60 min of metabolic inhibition most cells (83.1 ± 2%) presented rigor contracture without between-group differences. Reoxygenation resulted in hypercontracture of 84.2 ± 2.3, 91.2 ± 1.4 and 84.1 ± 2.1% of cells in TMZ, TMZ-Pre and control groups, P =NS. The trypan blue exclusion test revealed a higher proportion of cells with sarcolemmal integrity in TMZ and TMZ-Pre groups than in controls (12.7 ± 2.0, 10.0 ± 1.5 and 6.3 ± 0.8%, respectively, P = 0.002). No between-group differences in LDH activity in the extracellular medium were observed at the onset or at the end of metabolic inhibition. However, LDH release was significantly lower (P = 0.002) in the TMZ-Pre group (1.6 ± 0.1 IU/1000 cells) than in the TMZ and control groups (1.9 ± 0.2 and 2.2 ± 0.1 IU/1000 cells).Conclusion: Preincubation of cardiomyocytes with TMZ does not prevent rigor contracture induced by metabolic inhibition or hypercontracture during subsequent reoxygenation, but does improve sarcolemmal resistance to reoxygenation-induced mechanical stress. This could help to explain the beneficial effect of TMZ on infarct size.

KEYWORDS Sarcolemma; Cytoskeleton; Osmotic swelling; Reoxygenation; Reperfusion; Cell viability; Myocardial ischemia; Myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
H.M. Piper, D. Garcna-Dorado, and M. Ovize
A fresh look at reperfusion injury
Cardiovasc Res, May 1, 1998; 38(2): 291 - 300.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.